{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:31:15Z","timestamp":1780450275414,"version":"3.54.1"},"reference-count":33,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"UCB Japan Co. Ltd"},{"name":"AbbVie GK"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.2217\/imt-2023-0058","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T13:42:42Z","timestamp":1707226962000},"page":"273-285","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0299-7943","authenticated-orcid":false,"given":"Michio","family":"Tokuyama","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tokai University School of Medicine, Isehara, Kanagawa, 2591193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Mabuchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tokai University School of Medicine, Isehara, Kanagawa, 2591193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80507-7"},{"key":"e_1_3_6_6_1","first-page":"37","article-title":"An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy","volume":"8","author":"Soriano E","year":"2016","unstructured":"Soriano E , Acosta Felquer ML , Rosa J . An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatol. Res. Rev. 8, 37\u201344 (2016).","journal-title":"Open Access Rheumatol. Res. Rev."},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S31658"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq031"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.2.11271"},{"key":"e_1_3_6_10_1","unstructured":"Pharmaceuticals and Medical Devices Agency . Interview form of certolizumab pegol in Japan. https:\/\/amn.astellas.jp\/content\/dam\/jp\/amn\/jp\/ja\/di\/doc\/Pdfs\/DocNo202211190_y.pdf?redirect=false (Accessed 25 November 2023 )."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00026-1"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/11717"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20225"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2009.06.009"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-016-0245-0"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker302"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1997.00326.x"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211384"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.012"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.013"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00520-0"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"e_1_3_6_27_1","doi-asserted-by":"crossref","first-page":"e000582","DOI":"10.1136\/rmdopen-2017-000582","article-title":"4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis","volume":"4","author":"van der Heijde D","year":"2018","unstructured":"van der Heijde D , Deodhar A , FitzGerald O et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 4, e000582 (2018).","journal-title":"RMD Open"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40851"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00741-x"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19314"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"issue":"5","key":"e_1_3_6_32_1","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni CE","year":"2008","unstructured":"Antoni CE , Kavanaugh A , van der Heijde D et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J. Rheumatol. 35(5), 869\u2013876 (2008).","journal-title":"J. Rheumatol."},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.6.719"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204902"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2023-0058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:14:16Z","timestamp":1715955256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2023-0058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.2217\/imt-2023-0058"],"URL":"https:\/\/doi.org\/10.2217\/imt-2023-0058","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}